Kymera Therapeutics Inc. (KYMR)
Kymera Therapeutics Statistics
Share Statistics
Kymera Therapeutics has 64.94M shares outstanding. The number of shares has increased by 5.84% in one year.
| Shares Outstanding | 64.94M |
| Shares Change (YoY) | 5.84% |
| Shares Change (QoQ) | 0.28% |
| Owned by Institutions (%) | 94.22% |
| Shares Floating | 53.43M |
| Failed to Deliver (FTD) Shares | 27.35K |
| FTD / Avg. Volume | 3.83% |
Short Selling Information
The latest short interest is 7.37M, so 11.35% of the outstanding shares have been sold short.
| Short Interest | 7.37M |
| Short % of Shares Out | 11.35% |
| Short % of Float | 12.67% |
| Short Ratio (days to cover) | 6.93 |
Valuation Ratios
The PE ratio is -13.49 and the forward PE ratio is -8.35. Kymera Therapeutics's PEG ratio is -0.74.
| PE Ratio | -13.49 |
| Forward PE | -8.35 |
| PS Ratio | 64.14 |
| Forward PS | 3.7 |
| PB Ratio | 3.61 |
| P/FCF Ratio | -14.56 |
| PEG Ratio | -0.74 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kymera Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.53, with a Debt / Equity ratio of 0.11.
| Current Ratio | 7.53 |
| Quick Ratio | 7.53 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | -0.41 |
| Debt / FCF | -0.42 |
| Interest Coverage | -1050.74 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $250.38K |
| Profits Per Employee | $-1.19M |
| Employee Count | 188 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -5.33% in the last 52 weeks. The beta is 2.23, so Kymera Therapeutics's price volatility has been higher than the market average.
| Beta | 2.23 |
| 52-Week Price Change | -5.33% |
| 50-Day Moving Average | 30.5 |
| 200-Day Moving Average | 40.81 |
| Relative Strength Index (RSI) | 66.27 |
| Average Volume (20 Days) | 713.35K |
Income Statement
In the last 12 months, Kymera Therapeutics had revenue of 47.07M and earned -223.86M in profits. Earnings per share was -2.98.
| Revenue | 47.07M |
| Gross Profit | 39.7M |
| Operating Income | -261.63M |
| Net Income | -223.86M |
| EBITDA | -216.24M |
| EBIT | -223.61M |
| Earnings Per Share (EPS) | -2.98 |
Balance Sheet
The company has 120.26M in cash and 87.76M in debt, giving a net cash position of 32.49M.
| Cash & Cash Equivalents | 120.26M |
| Total Debt | 87.76M |
| Net Cash | 32.49M |
| Retained Earnings | -754.61M |
| Total Assets | 978.03M |
| Working Capital | 442.5M |
Cash Flow
In the last 12 months, operating cash flow was -194.5M and capital expenditures -12.84M, giving a free cash flow of -207.34M.
| Operating Cash Flow | -194.5M |
| Capital Expenditures | -12.84M |
| Free Cash Flow | -207.34M |
| FCF Per Share | -2.76 |
Margins
Gross margin is 84.34%, with operating and profit margins of -555.82% and -475.57%.
| Gross Margin | 84.34% |
| Operating Margin | -555.82% |
| Pretax Margin | -475.57% |
| Profit Margin | -475.57% |
| EBITDA Margin | -459.37% |
| EBIT Margin | -555.82% |
| FCF Margin | -440.47% |
Dividends & Yields
KYMR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for KYMR is $57, which is 66.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $57 |
| Price Target Difference | 66.1% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | 7.86 |
| Piotroski F-Score | 4 |